delgocitinib

a Janus kinase inhibitor

Also Known As:

1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)-; 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile; JTE-052

Networked: 39 relevant articles (12 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - delgocitinib: 39

Experts

1.	Kabashima, Kenji: 6 articles (10/2021 - 12/2016)
2.	Tanimoto, Atsuo: 6 articles (02/2020 - 01/2015)
3.	Nagata, Takeshi: 5 articles (10/2021 - 06/2018)
4.	Nakagawa, Hidemi: 5 articles (10/2021 - 06/2018)
5.	Nemoto, Osamu: 5 articles (10/2021 - 06/2018)
6.	Amano, Wataru: 5 articles (02/2020 - 01/2015)
7.	Igarashi, Atsuyuki: 4 articles (10/2021 - 12/2019)
8.	Saeki, Hidehisa: 4 articles (10/2021 - 12/2019)
9.	Matsushita, Mutsuyoshi: 4 articles (02/2020 - 01/2015)
10.	Kimoto, Yukari: 4 articles (01/2020 - 01/2015)

Related Diseases

1.	Atopic Dermatitis (Atopic Eczema) 07/01/2023 - "Delgocitinib shows that JAK-associated signaling is essential for the inflammatory reaction in atopic dermatitis, one of the common allergic diseases. " 12/01/2021 - "Delgocitinib in atopic dermatitis." 04/01/2020 - "This article summarizes the milestones in the development of delgocitinib leading to this first approval for the treatment of adults with atopic dermatitis. " 04/01/2020 - "Topical delgocitinib (Corectim®) is approved in Japan for the treatment of atopic dermatitis. " 08/01/2021 - "Successful treatment of severe blepharitis in a patient with atopic dermatitis by topical delgocitinib."
2.	Eczema 04/01/2020 - "The improvement in modified Eczema Area and Severity Index score was maintained in part 2. Most adverse events were mild and unrelated to delgocitinib across the study periods. " 04/01/2020 - "At the end of treatment in part 1, the least-squares mean percent changes from baseline in the modified Eczema Area and Severity Index score, the primary efficacy endpoint, were significantly greater in the delgocitinib group than in the vehicle group (-44.3% vs 1.7%, P < .001). " 01/01/2020 - "Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study." 12/01/2019 - "At EOT, modified Eczema Area and Severity Index scores in both delgocitinib groups were significantly reduced compared with that in the vehicle group. " 07/01/2023 - "To assess the effect of delgocitinib cream on itch, pain and nine additional key signs and symptoms reported by patients with CHE using the Hand Eczema Symptom Diary (HESD). "
3.	Pruritus (Itching) 12/01/2019 - "Similarly, all other efficacy parameters, including Investigator's Global Assessment and pruritus scores, in both delgocitinib groups were significantly improved compared with those in the vehicle group at EOT. " 01/01/2018 - "The JTE-052 groups also showed significant improvement in other parameters; notably, the pruritus NRS score was reduced as early as day 1 night-time. " 02/01/2020 - "Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model." 01/01/2023 - "Topical delgocitinib, tofacitinib, ruxolitinib, cerdulatinib and ifidancitinib are effective in treating AD and significantly improve EASI, IGA, pruritus-NRS score and some other indexes in adults. " 01/01/2023 - "Data discussed here support the use of steroid-sparing medications (tacrolimus, pimecrolimus, crisaborole, delgocitinib) as safe options with minimal adverse events for managing paediatric AD, although a larger number of TCI studies reported burning and pruritus compared to TCS studies. "
4.	Inflammation (Inflammations) 11/06/2015 - "Administration of JTE-052 completely improved the spontaneous locomotor activity, with partial reductions in articular inflammation and joint destruction. " 12/01/2016 - "JTE-052 potently inhibited T cell proliferation and activation by antigen presentation in vitro, and attenuated skin inflammation in a sensitized-lymphocyte transfer model without suppressing T cell migration. " 01/01/2021 - "The effectiveness of crisaborole reveals that PDE4 contributes to Th2 and Th17/Th22 inflammation and lesional skin barrier dysfunction, while delgocitinib shows that JAK-associated signaling is essential for the inflammatory reaction in AD. " 01/01/2018 - "A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents." 01/01/2015 - "In the collagen-induced arthritis model, JTE-052 ameliorated articular inflammation and joint destruction even in therapeutic treatments where methotrexate was ineffective. "
5.	Alopecia Areata 03/01/2023 - "A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata." 08/18/2023 - "Alopecia areata in a patient with cytotoxic T lymphocyte antigen-4 haploinsufficiency successfully treated with topical delgocitinib ointment." 08/01/2023 - "Successful management of severe alopecia areata and vitiligo using topical delgocitinib and a 308-nm excimer laser."

Related Drugs and Biologics

1.	Janus Kinase Inhibitors
2.	Ointments (Pastes)
3.	delgocitinib
4.	Methotrexate (Mexate)
5.	ruxolitinib
6.	tofacitinib
7.	4- (cyclopropylamino)- 2- ((4- (4- (ethylsulfonyl)piperazin- 1- yl)phenyl)amino)pyrimidine- 5- carboxamide
8.	Cyclosporine (Ciclosporin)
9.	Immunoglobulin A (IgA)
10.	Tacrolimus (Prograf)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Excimer Lasers